{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:38:43Z","timestamp":1793176723979,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,2,6]]},"abstract":"\n Importance<\/jats:title>\n Approximately 12 million adults in the US have a history of gout, but whether serum urate levels can help predict recurrence is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess associations of a single serum urate measurement with subsequent risk of acute gout flares and subsequent risk of hospitalizations for gout among patients in the UK with a history of gout.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective study included patients with a history of gout identified from the UK between 2006 and 2010 who were followed up through Primary Care Linked Data medical record linkage until 2017 and through the Hospital Episode Statistics database until 2020.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Serum urate levels at enrollment.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n Rate of recurrent acute gout, ascertained by hospitalization, outpatient, and prescription\/procedure records, and adjusted rate ratios using negative binomial regressions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 3613 patients with gout (mean age, 60 years; 3104 [86%] men), 1773 gout flares occurred over a mean follow-up of 8.3 years. Of these, 1679 acute gout flares (95%) occurred in people with baseline serum urate greater than or equal to 6 mg\/dL and 1731 (98%) occurred in people with baseline serum urate greater than or equal to 5 mg\/dL. Rates of acute gout flares per 1000 person-years were 10.6 for participants with baseline urate levels less than 6 mg\/dL, 40.1 for levels of 6.0 to 6.9 mg\/dL, 82.0 for levels of 7.0 to 7.9 mg\/dL, 101.3 for levels of 8.0 to 8.9 mg\/dL, 125.3 for urate levels of 9.0 to 9.9 mg\/dL, and 132.8 for levels greater than or equal to 10 mg\/dL. Rate ratio of flares were 1.0, 3.37, 6.93, 8.67, 10.81, and 11.42, respectively, over 10 years (1.61 [1.54-1.68] per mg\/dL). Rates of hospitalization per 1000 person-years during follow-up were 0.18 for those with baseline serum urate less than 6 mg\/dL, 0.97 for serum urate of 6.0 to 6.9 mg\/dL, 1.8 for serum urate of 7.0 to 7.9 mg\/dL, 2.2 for serum urate of 8.0 to 8.9 mg\/dL, 6.7 for serum urate of 9.0 to 9.9 mg\/dL, and 9.7 for serum urate greater than or equal to 10 mg\/dL. Rate ratios of hospitalization for gout, adjusting for age, sex, and race were 1.0, 4.70, 8.94, 10.37, 33.92, and 45.29, respectively (1.87 [1.57-2.23] per mg\/dL).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this retrospective study of patients with a history of gout, serum urate levels at baseline were associated with the risk of subsequent gout flares and rates of hospitalization for recurrent gout. These findings support using a baseline serum urate level to assess risk of recurrent gout over nearly 10 years of follow-up.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.26640","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T12:54:46Z","timestamp":1707224086000},"page":"417","source":"Crossref","is-referenced-by-count":47,"title":["Serum Urate and Recurrent Gout"],"prefix":"10.1001","volume":"331","author":[{"given":"Natalie","family":"McCormick","sequence":"first","affiliation":[{"name":"Rheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Arthritis Research Canada, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chio","family":"Yokose","sequence":"additional","affiliation":[{"name":"Rheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Challener","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit D.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruthi","family":"Tanikella","sequence":"additional","affiliation":[{"name":"Rheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[{"name":"Rheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston"},{"name":"The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Arthritis Research Canada, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"joi230157r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.9501","article-title":"Trends in prevalence of gout among US Asian adults, 2011-2018.","volume":"6","author":"Yokose","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"joi230157r2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout.","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"issue":"5","key":"joi230157r3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","article-title":"Association between gout flare and subsequent cardiovascular events among patients with gout.","volume":"328","author":"Cipolletta","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"joi230157r4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.v75.9","article-title":"Risk of venous thromboembolism with gout flares.","volume":"75","author":"Cipolletta","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"joi230157r5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout.","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"joi230157r7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study.","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"issue":"4","key":"joi230157r8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/art.v62:4","article-title":"Epidemiology of gout in women: fifty-two-year follow-up of a prospective cohort.","volume":"62","author":"Bhole","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"joi230157r9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","article-title":"Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"joi230157r10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jacc.2021.03.342","article-title":"United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6\/8.","volume":"78","author":"Caleyachetty","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"joi230157r11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population.","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"9","key":"joi230157r12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/art.v75.9","article-title":"Prediagnostic glycoprotein acetyl levels and incident and recurrent flare risk accounting for serum urate levels: a population-based, prospective study and mendelian randomization analysis.","volume":"75","author":"Joshi","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"joi230157r15","doi-asserted-by":"publisher","first-page":"R224","DOI":"10.1186\/ar4425","article-title":"Veterans Affairs databases are accurate for gout-related health care utilization: a validation study.","volume":"15","author":"Singh","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"joi230157r16","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/acr.v66.11","article-title":"Using natural language processing and machine learning to identify gout flares from electronic clinical notes.","volume":"66","author":"Zheng","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"joi230157r17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","article-title":"Frequency and risk factors of gout flares in a large population-based cohort of incident gout.","volume":"50","author":"Rothenbacher","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"joi230157r18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjmed.2013.12.019","article-title":"Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study.","volume":"127","author":"Neogi","year":"2014","journal-title":"Am J Med"},{"issue":"9","key":"joi230157r19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks.","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"joi230157r20","first-page":"1341","article-title":"Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study.","volume":"33","author":"Hunter","year":"2006","journal-title":"J Rheumatol"},{"issue":"12","key":"joi230157r21","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1002\/art.v64.12","article-title":"Cherry consumption and decreased risk of recurrent gout attacks.","volume":"64","author":"Zhang","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"joi230157r22","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.v72.6","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout.","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"joi230157r23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout.","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"joi230157r24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The British Society for Rheumatology Guideline for the Management of Gout.","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"joi230157r25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/art.v15:2","article-title":"The influence of temperature on the solubility of monosodium urate.","volume":"15","author":"Loeb","year":"1972","journal-title":"Arthritis Rheum"},{"issue":"5","key":"joi230157r26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/art.v8:4","article-title":"The acute attack of gouty arthritis.","volume":"8","author":"Seegmiller","year":"1965","journal-title":"Arthritis Rheum"},{"issue":"10","key":"joi230157r27","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1136\/ard.45.10.858","article-title":"Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates.","volume":"45","author":"Burt","year":"1986","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"joi230157r28","first-page":"1042","article-title":"The role of serum and synovial fluid components in the promotion of urate crystal formation.","volume":"18","author":"McGill","year":"1991","journal-title":"J Rheumatol"},{"issue":"4","key":"joi230157r29","first-page":"684","article-title":"Gouty arthritis in nodal osteoarthritis.","volume":"23","author":"Fam","year":"1996","journal-title":"J Rheumatol"},{"issue":"1","key":"joi230157r30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","article-title":"The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.","volume":"15","author":"Halpern","year":"2009","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"joi230157r31","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.080487","article-title":"Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?","volume":"36","author":"Wu","year":"2009","journal-title":"J Rheumatol"},{"issue":"9","key":"joi230157r32","first-page":"1950","article-title":"The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.","volume":"29","author":"Urano","year":"2002","journal-title":"J Rheumatol"},{"issue":"6","key":"joi230157r33","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3899\/jrheum.080938","article-title":"Serum urate during acute gout.","volume":"36","author":"Schlesinger","year":"2009","journal-title":"J Rheumatol"},{"key":"joi230157r6","volume-title":"Harrison\u2019s Principles of Internal Medicine","author":"Choi","year":"2022","edition":"21st ed"},{"key":"joi230157r13","unstructured":"Primary Care Linked Data: Version 1.0. UK Biobank; 2019. Accessed January 2, 2024. https:\/\/biobank.ctsu.ox.ac.uk\/crystal\/refer.cgi?id=591"},{"key":"joi230157r14","unstructured":"Companion Document to Accompany Serum Biomarker Data. UK Biobank; 2019. Accessed January 2, 2024. https:\/\/biobank.ctsu.ox.ac.uk\/crystal\/ukb\/docs\/serum_biochemistry.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2814538\/jama_mccormick_2024_oi_230157_1707332369.64017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T11:18:29Z","timestamp":1707391109000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2814538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2,6]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.26640","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}